News & events Upcoming events Oct 11, 2023 - Oct 13, 2023 ECTRIMS 2023 - 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Milano, Italy More info and meet us there Oct 11, 2023 - Oct 13, 2023 JFBM 2023 (Journées Francophones de Biologie Médicale) Antibes, Juan-les-Pins, France More info and meet us there Oct 12, 2023 - Oct 13, 2023 DGKL 2023 - Laboratoriumsmedizin in Zeiten der Transformation Mannheim, Germany More info and meet us there See all upcoming events Latest news Aug 8, 2023 Fujirebio joins the Global Health Innovative Technology (GHIT) Fund H.U. Group Holding Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa; Head Office: Minato-ku... Read more Jul 17, 2023 Beckman Coulter and Fujirebio partner to bolster access to patient-friendly, blood-based Alzheimer’s disease test therapeutics Collaboration builds upon Fujirebio expertise in neurodegenerative disease assays and Beckman Coulter’s high sensitivity, high throughput... Read more Mar 31, 2023 Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G... Read more Mar 28, 2023 Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more Mar 8, 2023 AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. announce strategic partnership to advance biomarker development for Alzheimer’s disease and neurodegeneration San Diego, CA and Tokyo, Japan and Malvern, PA – March 8, 2023 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics... Read more Nov 7, 2022 Fujirebio acquires Fluxus to accelerate new platform development based on ultra-high sensitivity detection technology H.U. Group Holding Inc., and its wholly-owned subsidiary, Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Shinjuku-ku... Read more Load More
Oct 11, 2023 - Oct 13, 2023 ECTRIMS 2023 - 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis Milano, Italy More info and meet us there
Oct 11, 2023 - Oct 13, 2023 JFBM 2023 (Journées Francophones de Biologie Médicale) Antibes, Juan-les-Pins, France More info and meet us there
Oct 12, 2023 - Oct 13, 2023 DGKL 2023 - Laboratoriumsmedizin in Zeiten der Transformation Mannheim, Germany More info and meet us there
Aug 8, 2023 Fujirebio joins the Global Health Innovative Technology (GHIT) Fund H.U. Group Holding Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (President and CEO: Goki Ishikawa; Head Office: Minato-ku... Read more
Jul 17, 2023 Beckman Coulter and Fujirebio partner to bolster access to patient-friendly, blood-based Alzheimer’s disease test therapeutics Collaboration builds upon Fujirebio expertise in neurodegenerative disease assays and Beckman Coulter’s high sensitivity, high throughput... Read more
Mar 31, 2023 Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse® G ApoE4 and Lumipulse® G Pan-ApoE assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G... Read more
Mar 28, 2023 Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse® G NfL CSF and Lumipulse® G NfL Blood tests Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 28, 2023 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more
Mar 8, 2023 AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. announce strategic partnership to advance biomarker development for Alzheimer’s disease and neurodegeneration San Diego, CA and Tokyo, Japan and Malvern, PA – March 8, 2023 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics... Read more
Nov 7, 2022 Fujirebio acquires Fluxus to accelerate new platform development based on ultra-high sensitivity detection technology H.U. Group Holding Inc., and its wholly-owned subsidiary, Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Shinjuku-ku... Read more
